Mizuho analyst Salim Syed joins Analyst Thursdays to talk about this week’s news from Cytokinetics, Gilead, and more
Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, BridgeBio’s possible reaction to HELIOS-B, and Vaxcyte’s pneumococcal vaccine readout coming up later this year.